Skip to main content

Alexion - Fundamentalanalyse - Jahresbericht / Bilanz / Geschäftsbericht

Alexion Pharmaceuticals (ISIN: US0153511094, WKN: 899527) Kursdatum: 21.07.2017 Kurs: 131,790 USD
Beschreibung Daten
Symbol ALXN
Marktkapitalisierung 29.916.329.984,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ 100NASDAQ Comp.S&P 500
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 2011-05-23 - 2:1 | 2008-08-25 - 2:1 |
Internet
Letztes Bilanz Update 16.02.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 21.07.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
39,73 27,55 0,00% 3,01 65,60 74,88 9,71 3,44

Firmenbeschreibung

Quarterly Financial Information (unaudited)The following condensed quarterly financial information is for the years ended December 31, 2015 and 2014: March 31 June 30 September 30 December 31 2015:        Revenues$600,333 $636,210 $666,637 $700,867 Cost of sales69,399(1)52,007 54,057 57,626 Operating expenses427,227 403,121(2)458,012(3)545,927(3)Operating income103,707 181,082 154,568 97,314 Net income (loss)$91,323 $170,215 $(183,757)(4)$66,604 Earnings (loss) per common share        Basic$0.46 $0.84 $(0.81) $0.30 Diluted$0.45 $0.83 $(0.81) $0.29           March 31 June 30 September 30 December 31 2014:        Revenues$566,616(5)$512,495 $555,146 $599,476 Cost of sales32,939(5)39,626 51,858 49,439 Operating expenses324,174 254,020 266,629 346,342(6)Operating income209,503 218,849 236,659 203,695 Net income$159,354 $166,495 $177,731 $153,332 Earnings per common share        Basic$0.81 $0.84 $0.90 $0.77

Firmenstrategie

The accompanying consolidated financial statements include the accounts of Alexion and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. For each of our business combinations, all of the assets acquired and liabilities assumed were recorded at their respective fair values as of the date of acquisition, and their results of operations are included in the consolidated financial statements from the date of acquisition.

RevenueRecognitionPolicyTextBlock

We record distribution and other fees paid to our customers as a reduction of revenue, unless we receive an identifiable and separate benefit for the consideration and we can reasonably estimate the fair value of the benefit received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.

We enter into foreign exchange forward contracts to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, that are denominated in currencies other than the U.S. dollar. These hedges are designated as cash flow hedges upon inception. We record the effective portion of these cash flow hedges to revenue in the period in which the sale is made to an unrelated third party and the derivative contract is settled.

SegmentReportingDisclosureTextBlock

Segment Information

We operate as one business segment, which is the innovation, development and commercialization of life-transforming therapeutic products. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with our management reporting. Disclosures about net product sales and long-lived assets by geographic area are presented below.

Net product sales

Net product sales by product are as follows:

 
Year Ended December 31,
 
2015
 
2014
 
2013
Net product sales:
 
 
 
 
 
Soliris (1)
$
2,590,197

 
$
2,233,733

 
$
1,551,346

Strensiq
11,969

 

 

Kanuma
366

 

 

 
$
2,602,532

 
$
2,233,733

 
$
1,551,346


Geographical information

 
Year Ended December 31,
Net product sales:
2015
 
2014
 
2013
United States
$
951,307

 
$
730,089

 
$
561,405

Europe (1)
840,465

 
836,134

 
514,987

Asia Pacific
276,350

 
244,059

 
203,538

Other
534,410

 
423,451

 
271,416

 
$
2,602,532

 
$
2,233,733

 
$
1,551,346

(1) As described in Note 19, "Quarterly Financial Information (unaudited)", included within the Soliris and Europe revenues for 2014 is a reimbursement of $87,830 for shipments made in years prior to January 1, 2014 as a result of an agreement with the French government.
 
 
 
 
 
 
 
 
 
December 31,
Long-lived assets (2):
 
 
2015
 
2014
United States
 
 
$
444,282

 
$
298,122

Europe
 
 
247,474

 
88,543

Other
 
 
5,269

 
5,583

 
 
 
$
697,025

 
$
392,248

(2)
Long-lived assets consist of property, plant and equipment.

EarningsPerSharePolicyTextBlock

Basic earnings per common share (EPS) are computed by dividing net income by the weighted-average number of shares of common stock outstanding. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method

We exclude from EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of EPS for the years ended December 31, 2015, 2014 and 2013 were 2,450, 1,099, and 2,243 shares of common stock, respectively, because their effect is anti-dilutive.